
Pfizer Secures Up to $1.5 Billion for Monthly Obesity Drug Trials
Pfizer has secured up to $1.5 billion from Blackstone Life Sciences to fund development of berobenatide through the end of 2028. The experimental GLP-1 receptor agonist is being studied as a once-monthly injection for chronic weight management.









